Amgen To Webcast Investor Call At EADV 2021

- September 29th, 2021

Amgen will host a webcast call for the investment community in conjunction with the European Academy of Dermatology and Venereology 2021 Congress. On Monday, Oct. 4, 2021, at 8:30 a.m. ET, David M. Reese M.D., executive vice president of Research and Development at Amgen, along with other members of Amgen’s management team, will discuss clinical data being presented at EADV, including data from the AMG …

– Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Academy of Dermatology and Venereology (EADV) 2021 Congress. On Monday, Oct. 4, 2021, at 8:30 a.m. ET, David M. Reese M.D., executive vice president of Research and Development at Amgen, along with other members of Amgen’s management team, will discuss clinical data being presented at EADV, including data from the AMG 451KHK4083 Phase 2 trial in patients with moderate-to-severe atopic dermatitis, as well as our broader inflammation portfolio.

Live audio of the investor call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen’s business given at certain investor and medical conferences, can be accessed on Amgen’s website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen .

CONTACT: Amgen, Thousand Oaks
Michael Strapazon , 805-313-5553 (media)
Trish Rowland , 805-447-5631(media)
Arvind Sood , 805-447-1060 (investors)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-webcast-investor-call-at-eadv-2021-301388248.html

SOURCE Amgen

News Provided by Canada Newswire via QuoteMedia

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Tags

Tags: ,

Leave a Reply